Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training
Compass Pathways (Nasdaq: CMPS) selected psychedelic-therapy educator Fluence to develop a post-approval provider training certificate program for COMP360, its investigational synthetic psilocybin treatment for treatment-resistant depression. The program prepares clinicians to support patients through the COMP360 treatment experience ahead of potential FDA approval and commercial availability, and progresses through three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification.
Key figures
- Drug Name
- COMP360
- Indication
- treatment-resistant depression
- Training modules
- 3
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.